1-15 of 15
Boris Gorsh
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Anchored Matching Adjusted Indirect Treatment Comparison of Quizartinib Vs Midostaurin in Newly Diagnosed Patients with FLT3-ITD-Positive Acute Myeloid Leukaemia

Nishan Shaik, Harry P. Erba, Sudhir Unni, Svenja Petersohn, Elizabeth Westerberg, Boris Gorsh, Akash Nahar, Kristy Burns, Sonja Kroep
Journal: Blood
Blood (2024) 144 (Supplement 1): 1509.
https://doi.org/10.1182/blood-2024-209799
Published: 2024
Journal Articles

Anemia and Transfusion Dependency Are Important Prognostic Factors for Overall Survival in Patients with Myelofibrosis: Results of a Real-World Analysis of Medicare Patients

Aaron T. Gerds, Ruben A. Mesa, Joseph Tkacz, Laura Moore-Schiltz, Jill Schinkel, Kelesitse Phiri, Tom Liu, Boris Gorsh
Journal: Blood
Blood (2023) 142 (Supplement 1): 6418.
https://doi.org/10.1182/blood-2023-178012
Published: 2023
Journal Articles

Estimating Transfusion-Related Medical Costs and Associated Time Burden in Patients with Myelofibrosis: A Comparison of Momelotinib Vs Ruxolitinib Based on Simplify-1

Lucia Masarova, Tom Liu, Mirko Fillbrunn, Weilong Li, Gautam Sajeev, Sumati Rao, Boris Gorsh, James Signorovitch
Journal: Blood
Blood (2023) 142 (Supplement 1): 4571.
https://doi.org/10.1182/blood-2023-181185
Published: 2023
Journal Articles

Red Blood Cell Transfusion Independence Status Is an Independent Predictor of Survival: A Post Hoc Time-Dependent Analysis of the Phase 3 Simplify-1, Simplify-2, and Momentum Trials

Vikas Gupta, Claire N Harrison, Boris Gorsh, Bharat Patel, Zhaohui Wang, Molly Purser, Catherine Ellis, Bryan Strouse, Dwaipayan Patnaik, Jun Kawashima, Ruben A. Mesa
Journal: Blood
Blood (2023) 142 (Supplement 1): 3188.
https://doi.org/10.1182/blood-2023-178772
Published: 2023
Journal Articles

Time without Transfusion Reliance or Anemia Worsening: A Novel Method for Integrating Transfusion Dependence, Anemia, and Survival with Myelofibrosis Therapies Based on the Phase 3 Simplify-1 and Simplify-2 Trials

Ruben A. Mesa, Moshe Talpaz, Flora Mazerolle, Boris Gorsh, Manal M'Hari, Antoine Regnault, Catherine Ellis, Zhaohui Wang, Molly Purser, Tom Liu, Bryan Strouse, Dwaipayan Patnaik
Journal: Blood
Blood (2023) 142 (Supplement 1): 1826.
https://doi.org/10.1182/blood-2023-177784
Published: 2023
Journal Articles

Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified By Exposure to Lenalidomide or Anti-CD38 Therapy and Double-Class Refractory Status: A Retrospective Electronic Health Record Database Study

Joshua Richter, Peter Feng Wang, Alexa Molinari, Boris Gorsh, Natalie Boytsov, Suzanne Landi, Sue Perera, Prani Paka, Teresa Palumbo, Mei Sheng Duh, Christopher Yee, Anamika Khanal, Sonia Gupta, Ajai Chari
Journal: Blood
Blood (2022) 140 (Supplement 1): 4338–4340.
https://doi.org/10.1182/blood-2022-164918
Published: 2022
Journal Articles

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

Ajay K. Nooka, Adam Cohen, Hans C. Lee, Ashraf Z. Badros, Attaya Suvannasankha, Natalie Callander, Al-Ola Abdallah, Suzanne Trudel, Ajai Chari, Edward Libby, Maria Chaudhry, Malin Hultcrantz, Martin Kortuem, Paul G. Richardson, Rakesh Popat, Douglas W. Sborov, Shawn Hakim, Eric Lewis, Bharat Bhushan, Boris Gorsh, Ira Gupta, Joanna Opalinska, Sagar Lonial
Journal: Blood
Blood (2022) 140 (Supplement 1): 7301–7303.
https://doi.org/10.1182/blood-2022-164877
Published: 2022
Journal Articles

The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World

Attaya Suvannasankha, Thomas W. LeBlanc, Julia R. Correll, Chloe Carmichael, Boris Gorsh, Mona Martin, Helen Kitchen, Laurie Eliason, Madeleine Thursfield, Natalie Boytsov, Eva Brown Hajdukova, Mary Beth Lewis, Christine Mackay, Prani Paka, Alicia O'Neill, Sue Perera, Shivaranjani Naine, Alexa Molinari, Maya Hanna, David Kleinman
Journal: Blood
Blood (2022) 140 (Supplement 1): 13264–13266.
https://doi.org/10.1182/blood-2022-159637
Published: 2022
Journal Articles

Efficacy and Safety of Third-Line or Later (3L+) Treatments, Including the CD38 Monoclonal Antibody Class, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review

Maya Hanna, Justyna Chorazy, Ike Iheanacho, Boris Gorsh, Peter Feng Wang, Prani Paka, Sue Perera
Journal: Blood
Blood (2022) 140 (Supplement 1): 12559–12560.
https://doi.org/10.1182/blood-2022-167521
Published: 2022
Journal Articles

Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies

Natalie Boytsov, Boris Gorsh, Seth Anderson, Peter Feng Wang, Sue Perera, Meg Franklin
Journal: Blood
Blood (2022) 140 (Supplement 1): 12554–12555.
https://doi.org/10.1182/blood-2022-167184
Published: 2022
Journal Articles

Treatment Preferences of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, Spain, Italy, and Germany: Results from a Discrete Choice Experiment

Rakesh Popat, Sikander Ailawadhi, David Kleinman, Sue Perera, Boris Gorsh, Caitlin Thomas, Sarah Mulnick, Alicia O'Neill, Melissa Ross, Prani Paka, Maya Hanna, Alexa Molinari, Shivaranjani Naine, Heather Gelhorn
Journal: Blood
Blood (2022) 140 (Supplement 1): 7211–7213.
https://doi.org/10.1182/blood-2022-164795
Published: 2022
Journal Articles

Treatment Patterns and Outcomes of Patients with Double-Class Refractory or Triple-Class Refractory Multiple Myeloma: A Retrospective US Electronic Health Record Database Study

Feng Wang, Boris Gorsh, Maral DerSarkissian, Prani Paka, Rachel Bhak, Natalie Boytsov, Miriam L. Zichlin, Leah Sansbury, Christopher W. Yee, Shannon Ferrante, Anamika Khanal, Ahmed Noman, Mei Sheng Duh
Journal: Blood
Blood (2021) 138 (Supplement 1): 2705.
https://doi.org/10.1182/blood-2021-152301
Published: 2021
Journal Articles

Current Clinical Practice and Decision-Making in Multiple Myeloma Treatment in the United States of America: A Real-World Survey

Amanda Ribbands, Boris Gorsh, Abigail Bailey, Natalie Boytsov, Emily Luke, Annabel Lambert, Cosmina Hogea
Journal: Blood
Blood (2021) 138 (Supplement 1): 3001.
https://doi.org/10.1182/blood-2021-151281
Published: 2021
Journal Articles

DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Sagar Lonial, MD FACP, Peter M. Voorhees, MD, Simona Degli Esposti, MD, Ira Gupta, MD, Joanna Opalinska, MD, Sandhya Sapra, PhD, Boris Gorsh, PharmD, Zangdong He, PhD, David M Kleinman, MD, Debra Schaumberg, OD, MPH, ScD, Angely Loubert, PharmD, MSc, Juliette Meunier, MSc, Antoine Regnault, PhD, Laurie Eliason, MPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–28.
https://doi.org/10.1182/blood-2020-140013
Published: 2020
Journal Articles

Patient-Reported Experiences during and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study

Laurie Eliason, MPH, Julia Correll, MPH, Mona Martin, MPA, Anna Cardellino, MPH, Joanna Opalinska, MD, Trisha Piontek, BSN, Boris Gorsh, PharmD, Sandhya Sapra, PhD, Rakesh Popat
Journal: Blood
Blood (2020) 136 (Supplement 1): 1.
https://doi.org/10.1182/blood-2020-139395
Published: 2020